Liraglutide: A once-daily human glucagon-like peptide-1 analogue

Journal of Endocrinological Investigation

Volumn 32, Issue 8, 2009, Pages 701-703

  Aimaretti, G ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

GLP 1 analogue; Liraglutide; Type 2 diabetes mellitus

Indexed keywords

GLIMEPIRIDE; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIRAGLUTIDE; METFORMIN; PLACEBO; ROSIGLITAZONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

EID: 72449170966     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345744     Document Type: Note

References (22)

1. Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes 2008, 57 (Suppl 1): A164.
2. Agerse H, Jensen LB, Elbrand B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45: 195-202. (Pubitemid 34208381)
3. Elbrand B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002, 25: 1398-1404 (Pubitemid 41071152)
4. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53: 1187-1194
5. Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003, 140: 123-132
6. Bock T, Pakkenberg B, Buschard K. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS 2003, 111: 1117-1124 (Pubitemid 38091251)
7. Bregenholt S, Meldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005, 330: 577-584 (Pubitemid 40417684)
8. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002, 283: E745-52.
9. Ribel U, Larsen MO, Rolin B, et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 2002, 451: 217-225
10. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58: 975-983
11. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003, 52: 1786-1791 (Pubitemid 36792471)
12. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002, 51: 424-429 (Pubitemid 34764798)
13. McLaughlin T, Abbasi F, Kim HS, Lamendola C, Schaaf P, Reaven G. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. Metabolism 2001, 50: 795-800.
14. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101: 515-520 (Pubitemid 28084232)
15. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46: 798-801.
16. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30: 1608-1610
17. Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel treatment trial. Lancet 2009, 373: 473-481
18. Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009, 32: 84-90.
19. Marre M, Shaw J, Brändle M, et al; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26: 268-278
20. Zinman B, Gerich J, Buse JB, et al; LEAD-4 Study Investigators.. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009, 3: 1224-1230
21. Russell-Jones D, Vaag A, Schmitz O, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on tometformin and a sulfonylurea in type 2 diabetes. Diabetes 2008, 57 (Suppl 1): A159.
22. Madsbad S. Liraglutide effect and action in diabetes (LEAD™) trial. Expert Rev Endocrinol Metab 2009, 4: 119-129